Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
How effective is the use of genomic testing methods, such as tape strip tests, for assessing suspicious pigmented lesions in clinical practice?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
Would you favor radiation or immune modulating treatment like imiquimod to treat an uncomplicated basal cell carcinoma on the nose in an elderly patient for whom you'd like to avoid surgery?
When do you recommend SRT, if ever, for small SCCs and BCCs?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
Is there a general consensus on margins to use when treating SCCIS or BCC with ED&C?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
Have you used itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
